Showing 17 of 17 recruiting trials for “obsolete-syndromic-inherited-retinal-disorder”
A Phase 1/2 Study in Healthy Volunteers and Participants With Autosomal Dominant Retinitis Pigmentosa (RHO-adRP)
A Study of LX107 Gene Therapy in AIPL1-IRD Patients
🏥 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Jul 2025View details ↗
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
An Open-label, Dose-ascending Study of IGT001 for Retinitis Pigmentosa
🏥 Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine📍 1 site📅 Started Apr 2025View details ↗
Enrolling by InvitationNCT07056738 ↗
Prospective Exploratory Cohort Study on Ganglion Cell Degeneration in Retinitis Pigmentosa Patients
👨⚕️ Emilie Macé, Professor, Else Kroener Fresenius Center for Optogenetic Therapies, University Medical Center Goettingen📍 1 site📅 Started Mar 2025View details ↗
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
RecruitingNCT06323772 ↗
Natural History Study in Patients with PDE6A-, PDE6B- and RHO-linked Retinitis Pigmentosa
Safety and Tolerability Study of Gene Editing Drug ZVS203e in Participants With Retinitis Pigmentosa
A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa
👨⚕️ Janssen Pharmaceutical K.K., Japan Clinical Trial, Janssen Pharmaceutical K.K.📍 1 site📅 Started Sep 2023View details ↗
Safety and Tolerability of Intravitreal Administration of VG901 in Patients With Retinitis Pigmentosa Due to Mutations in the CNGA1 Gene
👨⚕️ Katarina Stingl, Center for Ophthalmology, University of Tuebingen📍 1 site📅 Started Sep 2023View details ↗
Enrolling by InvitationNCT05921162 ↗
A Long-Term Follow-Up Study in Subjects Who Received vMCO-I Administered Via Intravitreal Injection
Promising ROd-cone DYstrophy Gene therapY
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for NAION
👨⚕️ Chadwick Prodromos, MD, The Foundation for Orthopaedics and Regenerative Medicine📍 2 sites📅 Started Feb 2022View details ↗
RecruitingNCT04658251 ↗
Study of New Mutations in Cone Disorders
RecruitingNCT02471287 ↗
Genetics of Inherited Eye Disease
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →